You may have seen the news (7th June 2021) that the American FDA (Food and Drug Agency) has approved aducunamab (Aduhelm) for the treatment of mild Alzheimer’s Disease. This is the first new treatment for Alzheimer’s Disease licensed in some 20 years but is not yet licensed or available for use in the UK and we will await assessment by the UK drug regulator and NICE.
RICE was involved in one of the original studies with aducanumab and patients from that study are still involved here with ongoing evaluation of its safety and efficacy. Treatment with aducanumab is quite complex and is given intravenously and there are still concerns about how effective it is as a treatment; its initial use in the US will only be through a monitored programme to try and learn whether or not its use should continue. Nevertheless this is a landmark in the ongoing search for more effective treatments for Alzheimer’s disease and other types of dementia and RICE continues with its important clinical trial programme of other promising new therapies.